 |
인쇄하기
취소
|
Green Cross eying sales of 50 billion won with new drug
Published: 2011-08-17 06:56:00
Updated: 2011-08-17 06:56:00
Green Cross Corp. said Friday it has signed a co-promotion agreement with LG Life Sciences to market “Shinbaro,” a new drug for osteoarthritis in a bid to raise 50 billion won in domestic sales within the next five years.
Shinbaro is Korea’s fourth homegrown osteoarthritis medicine containing six herbs, such as Cibotium barometz J. Smith and Saposhnikovia divaricata Schiskin, and its efficac...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.